Bull case
ImmunityBio is positioned as a differentiated commercial-stage biotechnology company because ANKTIVA already has approved use in BCG-unresponsive NMIBC, while the ASCO 2026 lung readouts strengthen the case that its IL-15-driven immune-restoration mechanism can work beyond bladder cancer. In first-line NSCLC, ANKTIVA plus pembrolizumab improved median PFS to 7.0 months versus 2.2 months in TPS ≥50% patients and showed an OS signal of 34.7 months versus 20.2 months in chemotherapy-containing cohorts, with biomarker-linked lymphocyte expansion adding biological credibility. The bull thesis is further supported by stronger bladder-market durability versus pembrolizumab, NCCN Category 2A status in March '26, an FDA workshop that may favor papillary-only expansion, and a Tokyo-172 BCG supply strategy that could widen commercialization and near-term adoption.